AmpliPhi Biosciences Corporation
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AmpliPhi Biosciences Corporation
Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.
Turnstone’s initial public offering comes just one week after Apogee and Sagimet launched US IPOs. Also, Westlake Village BioPartners raised $450m for its third venture capital fund and argenx grossed $1.27bn in a post-Phase III follow-on offering.
On the heels of the FDA’s full approval of Biogen and Eisai’s Leqembi, AC Immune’s CEO is hopeful that a precision medicine approach with improved diagnosis, prevention and treatment of Alzheimer’s disease is not far down the road. With 16 clinical programs, notable partnerships and wholly owned assets, AC Immune holds a strong position to help reach that destination.
Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.
- Medical Devices
- Implantable Devices
- Other Names / Subsidiaries
- Biocontrol Limited
- Targeted Genetics Corporation (TGEN)
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.